ALBUQUERQUE, New Mexico, November 6 /PRNewswire/ --

- Breakthrough Medical Device Designed to Improve Quality of Life for Patients Suffering From Chronic Diseases

Kingfisher Americas, a healthcare company focused on improving patient quality of life, announced today that Kingfisher Healthcare has filed a U.S. Food and Drug Administration (FDA) 510(k) submission seeking clearance to market KFH Energy. The patented, high-tech medical device, designed to alleviate fatigue and pain, was successfully launched in the European market in September.

KFH Energy is a breakthrough product intended to improve quality of life for sufferers of chronic diseases such as post-polio syndrome, fibromyalgia, chronic fatigue syndrome and multiple sclerosis. The device, created for home use, utilizes Bio-Electric Stimulation Therapy (BEST) to enhance the body's physiological processes at the cellular level. The documented effects include an increase in ATP production, the molecule that delivers energy to all cells in the body, and increased synthesis of proteins. Kingfisher's KFH Energy encapsulates this unique technology in a convenient and easy-to-use device.

"We are excited to bring this revolutionary healthcare device to the United States and are eager to work closely with the FDA for the proper approvals," said Herb Whitaker, CEO of Kingfisher Americas. "The response we have received in Europe is promising and we look forward to improving the lives of many here in the Americas."

KFH Energy was recently awarded the CE mark in Europe. The company expects FDA approval by January 2008.

"The debilitating side effects of such chronic diseases, including polio, have gone untreated for far too long," said Dr. Henk Snyman, founder and CEO of Kingfisher Healthcare, the Belgium-based parent of Kingfisher Americas. "We are committed to providing these sufferers with a safe and natural solution and look forward to introducing this innovative solution to U.S. patients."

About Kingfisher Americas

Kingfisher Americas, a subsidiary of the Belgium-based Kingfisher Healthcare, is committed to providing proprietary natural energy devices and accessories. It utilizes a technology platform called BEST (Bio-Electric Stimulation Therapy) from which unique products are developed by Kingfisher Healthcare. Headquartered in Albuquerque, New Mexico, Kingfisher Americas focuses on establishing relationships with patients, patient support groups, and medical experts to improve the quality of life of fibromyalgia, post polio, and chronic fatigue syndrome patients. For more information, please visit http://www.kfamericas.com.

Media Contacts: Roy Whitaker, Kingfisher Americas, +1-877-252-4374 x-708, r.whitaker@kfhealth.com; Jackie Hanley, Racepoint Group, +1-781-487-4625, jhanley@racepointgroup.com.